228 related articles for article (PubMed ID: 34272305)
21. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
22. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
Spranger S; Luke JJ; Bao R; Zha Y; Hernandez KM; Li Y; Gajewski AP; Andrade J; Gajewski TF
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7759-E7768. PubMed ID: 27837020
[TBL] [Abstract][Full Text] [Related]
23. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.
Jung M; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DD; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ
Cancer Res; 2017 Feb; 77(4):971-981. PubMed ID: 27923830
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
Coronado E; Yañez Y; Vidal E; Rubio L; Vera-Sempere F; Cañada-Martínez AJ; Panadero J; Cañete A; Ladenstein R; Castel V; Font de Mora J
Mol Oncol; 2021 Feb; 15(2):364-380. PubMed ID: 33252831
[TBL] [Abstract][Full Text] [Related]
25. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
26. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
27. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
[TBL] [Abstract][Full Text] [Related]
29. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.
Layer JP; Kronmüller MT; Quast T; van den Boorn-Konijnenberg D; Effern M; Hinze D; Althoff K; Schramm A; Westermann F; Peifer M; Hartmann G; Tüting T; Kolanus W; Fischer M; Schulte J; Hölzel M
Oncoimmunology; 2017; 6(6):e1320626. PubMed ID: 28680756
[TBL] [Abstract][Full Text] [Related]
30. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
[TBL] [Abstract][Full Text] [Related]
31. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
32. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
33. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
[TBL] [Abstract][Full Text] [Related]
34. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
35. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
36. Immune expression in children with Wilms tumor: a pilot study.
Holl EK; Routh JC; Johnston AW; Frazier V; Rice HE; Tracy ET; Nair SK
J Pediatr Urol; 2019 Oct; 15(5):441.e1-441.e8. PubMed ID: 30981637
[TBL] [Abstract][Full Text] [Related]
37. Immunological landscape of Neuroblastoma and its clinical significance.
Batchu S
Cancer Treat Res Commun; 2021; 26():100274. PubMed ID: 33338852
[TBL] [Abstract][Full Text] [Related]
38. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
[TBL] [Abstract][Full Text] [Related]
39. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
40. Identification of an Autophagy-Related Risk Signature Correlates With Immunophenotype and Predicts Immune Checkpoint Blockade Efficacy of Neuroblastoma.
Kang W; Hu J; Zhao Q; Song F
Front Cell Dev Biol; 2021; 9():731380. PubMed ID: 34746127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
